Sources | Names Used |
---|---|
CTRPv2 | doxorubicin:navitoclax (2:1 mol/mol) |
PharmacoGx | doxorubicin:navitoclax (2:1 mol/mol) |
Feature Type | Standardized | Nominal ANOVA | ||||
---|---|---|---|---|---|---|
mRNA | CIB1 | CTRPv2 | pan-cancer | AAC | -0.16 | 5e-06 |
mRNA | HMGB1 | CTRPv2 | pan-cancer | AAC | 0.16 | 5e-06 |
mRNA | SMARCD1 | CTRPv2 | pan-cancer | AAC | 0.15 | 5e-06 |
mRNA | PTMA | CTRPv2 | pan-cancer | AAC | 0.17 | 5e-06 |
mRNA | ABRACL | CTRPv2 | pan-cancer | AAC | 0.16 | 5e-06 |
mRNA | C9orf24 | CTRPv2 | pan-cancer | AAC | 0.15 | 5e-06 |
mRNA | CCNJ | CTRPv2 | pan-cancer | AAC | 0.15 | 5e-06 |
mRNA | IQGAP1 | CTRPv2 | pan-cancer | AAC | -0.16 | 5e-06 |
mRNA | AVPI1 | CTRPv2 | pan-cancer | AAC | -0.16 | 5e-06 |
mRNA | TRO | CTRPv2 | pan-cancer | AAC | 0.17 | 5e-06 |